Similar articles

• Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.

  Dailey GE. Dailey GE. Drugs Today (Barc). 2015 Sep;51(9):519-35. doi: 10.1358/dot.2015.51.9.2368554. Drugs Today (Barc). 2015. PMID: 26488032 Review.
• Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.

  Alvarez CA, Neeland IJ, McGuire DK. Alvarez CA, et al. Diab Vasc Dis Res. 2015 Mar;12(2):74-7. doi: 10.1177/1479164114563303. Diab Vasc Dis Res. 2015. PMID: 25690133 Free PMC article. No abstract available.
• Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

  Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Petrykiv S, et al. Clin J Am Soc Nephrol. 2017 May 8;12(5):751-759. doi: 10.2215/CJN.10180916. Epub 2017 Mar 16. Clin J Am Soc Nephrol. 2017. PMID: 28302903 Free PMC article.
• Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.

  Levine MJ. Levine MJ. Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556. Curr Diabetes Rev. 2017. PMID: 27296042 Free PMC article. Review.
• Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.

  Škrtić M, Cherney DZ. Škrtić M, et al. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103. doi: 10.1097/MNH.0000000000000084. Curr Opin Nephrol Hypertens. 2015. PMID: 25470017 Review.